Information on glucocorticoid therapy in the main studies of biological agents - 01/10/11
Corresponding author. Tel.: +33 240 084 801; fax: +33 240 084 830.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
To evaluate reported information on prednisone therapy in the main studies of biological agents used to treat rheumatoid arthritis (RA).
Methods |
We reviewed 66 publications (including four abstracts), including 11 studies of infliximab, 19 of etanercept, eight of adalimumab, five of golimumab, four of certolizumab, four of rituximab, eight of abatacept, and seven of tocilizumab.
Results |
Whether concomitant prednisone therapy was used, it was specified in only 56 (85%) of the 66 publications. Only 42 (64%) publications indicated that the prednisone dosage remained unchanged throughout the study. The maximum prednisone dosage allowed was specified in only 39 (59%) reports and was lower than 8mg/day in only four (6%) studies. Data enabling determination of the mean daily prednisone dosage in prednisone-treated patients was available for only eight (12%) studies; the mean dosage ranged from 5.0 to 9mg/day (mean, 7.1±1.5). The percentage of patients receiving prednisone therapy was reported for only 41 (62%) studies. All the above-mentioned information was available in only two (3%) study reports. The percentage of patients on prednisone therapy ranged from 34% to 93% (mean, 58±13%) overall and varied across biological agents as follows: abatacept, 74.4%; golimumab, 67.9%; infliximab, 60.6%; certolizumab, 57.5%; rituximab, 57.5%; etanercept, 54.4%; tocilizumab, 52.8%; and adalimumab, 50.4%. These percentages did not decline between 1997 and 2010.
Conclusion |
Study reports provide inadequate information on prednisone therapy during biological treatment for RA.
Le texte complet de cet article est disponible en PDF.Keywords : Prednisone, Glucocorticoids, Infliximab, Etanercept, Adalimumab, Golimumab, Certolizumab, Rituximab, Abatacept, Tocilizumab
Plan
Vol 78 - N° 5
P. 478-483 - octobre 2011 Retour au numéro
Article précédent
- Melittin enhances apoptosis through suppression of IL-6/sIL-6R complex-induced NF-κB and STAT3 activation and Bcl-2 expression for human fibroblast-like synoviocytes in rheumatoid arthritis
- Seong-Kyu Kim, Ki-Yeun Park, Wern-Chan Yoon, Sung-Hoon Park, Kwan-Kyu Park, Dae-Hyun Yoo, Jung-Yoon Choe
- Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort
- Samy Slimani, Cédric Lukas, Bernard Combe, Jacques Morel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?